Back to Agenda
WED Session 2: CLINICAL TRIAL DATA TRANSPARENCY AND MAAS– HOW TO MOVE TO THE FUTURE?
Session Chair(s)
Noël Wathion, RPH
Deputy Executive Director
European Medicines Agency, Netherlands
Speaker(s)
EMA’s vision for Availability of Clinical Trial Information from Marketing Authorisation Applications and How it is to be Achieved
Noël Wathion, RPH
European Medicines Agency, Netherlands
Deputy Executive Director
What changes will new transparency provisions bring for researchers?
Catrin Tudur Smith
Liverpool University, United Kingdom
Reader in Medical Statistics
What does greater availability of clinical trial information mean for HTA?
Meindert Boysen, MPHARM, MSC
NICE Centre for Health Technology Evaluation (CHTE), United Kingdom
Programme Director Technology Appraisals, PASLU and HST
Have an account?